Monopar Therapeutics (NASDAQ:MNPR)
| Market Cap | $487.84M-12.0% |
| Revenue (ttm) | $0 |
| Net Income | -$6.21B-31846.2% |
| EPS | -$925.32-19.4% |
| Shares Out | 6.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 313,024 |
| Open | $70.11 |
| Previous Close | $71.73 |
| Day's Range | $67.22 - $74.40 |
| 52-Week Range | $50.07 - $124.82 |
| Beta | 1.61 |
| Analysts | Buy |
| Price Target | $126.00(+73.36%) |
| Earnings Date | Mar 25, 2027 |
About MNPR
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating MNPR in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Mar 25, 2027Earnings report
$MNPR stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MNPR holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MNPR's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MNPR Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MNPR patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MNPR from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MNPR
| VTIVanguard Morningstar Total Stock Market ETF | $12.73M |
| XBIState Street SPDR S&P Biotech ETF | $10.40M |
| IWMiShares Russell 2000 ETF | $8.49M |
| VXFVanguard Extended Market ETF | $4.26M |
| IWNiShares Russell 2000 Value ETF | $2.28M |
| VTWOVanguard Russell 2000 ETF | $2.09M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from MNPR’s recent data — informational, not investment advice
What’s Behind the Score
News check: Company reporting Q3 results and presenting clinical data for pipeline programs at major medical conference, indicating active development progress.
Recent Insider Activity
Insider Score Trend Over Time
-37.0 since Aug 28Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.
Frequently Asked Questions
ETFs that hold this stock
| BBC | Virtus Biotech Clinical Trials ETF | 0.89% |
| XBI | State Street SPDR S&P Biotech ETF | 0.10% |
| IWC | iShares Micro-Cap ETF | 0.08% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.05% |
| PWS | Pacer WealthShield ETF | 0.02% |
| LABU | Direxion Daily S&P Biotech Bull 3X Shares | 0.02% |
Weight is the stock’s share of each fund’s holdings.